Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline

Journals

Article Types

Countries / Regions

Search Results (1)

Search Parameters:
Keywords = Invivofectamine

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
22 pages, 3925 KiB  
Article
Chitosan siRNA Nanoparticles Produce Significant Non-Toxic Functional Gene Silencing in Kidney Cortices
by Mohamad-Gabriel Alameh, Ashkan Tavakoli Naeini, Garima Dwivedi, Frederic Lesage, Michael D. Buschmann and Marc Lavertu
Polymers 2024, 16(17), 2547; https://doi.org/10.3390/polym16172547 - 9 Sep 2024
Viewed by 1684
Abstract
Chitosan shows effective nucleic acid delivery. To understand the influence of chitosan’s molecular weight, dose, payload, and hyaluronic acid coating on in vivo toxicity, immune stimulation, biodistribution and efficacy, precisely characterized chitosans were formulated with unmodified or chemically modified siRNA to control for [...] Read more.
Chitosan shows effective nucleic acid delivery. To understand the influence of chitosan’s molecular weight, dose, payload, and hyaluronic acid coating on in vivo toxicity, immune stimulation, biodistribution and efficacy, precisely characterized chitosans were formulated with unmodified or chemically modified siRNA to control for innate immune stimulation. The hemocompatibility, cytokine induction, hematological and serological responses were assessed. Body weight, clinical signs, in vivo biodistribution and functional target knockdown were monitored. Hemolysis was found to be dose- and MW-dependent with the HA coating abrogating hemolysis. Compared to cationic lipid nanoparticles, uncoated and HA-coated chitosan nanoparticles did not induce immune stimulation or hematologic toxicity. Liver and kidney biomarkers remained unchanged with chitosan formulations, while high doses of cationic lipid nanoparticles led to increased transaminase levels and a decrease in body weight. Uncoated and HA-coated nanoparticles accumulated in kidneys with functional knockdown for uncoated chitosan formulations reaching 60%, suggesting potential applications in the treatment of kidney diseases. Full article
Show Figures

Graphical abstract

Back to TopTop